READ-ONLY DIGITIZATION RESULT
Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.
Blood Neoplasia · 2026-Aug · PMID 42436879
Panel E质量警告待 EXE 对齐验证
Time to progression from allo-HSCT
Figure 1. Survival endpoints. Similar outcomes in both treatment groups from randomization (A-B) and from time of allografting (C-F). The marks on the plot indicate censoring of individual patients. HR estimates and P values are based on a Cox model adjusted for the stratification factors used at randomization (age and AML type). Allo-HSCT, allogeneic HSCT; N, number of patients.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T16:45:17+00:00 |